Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation

被引:4
作者
Dulai, Rajdip [1 ,2 ,3 ]
Sulke, Neil [4 ]
Freemantle, Nick [4 ]
Lambiase, Pier D. [2 ]
Farwell, David [3 ]
Srinivasan, Neil T. [3 ,5 ]
Tan, Stuart [3 ]
Patel, Nikhil [1 ]
Graham, Adam [6 ]
Veasey, Rick A. [1 ,2 ]
机构
[1] East Sussex Hosp NHS Trust, Eastbourne Dist Gen Hosp, Cardiol Res Dept, Kings Dr, Eastbourne BN21 2UD, England
[2] UCL, Inst Cardiovasc Sci, London, England
[3] Mid & South Essex NHS Fdn Trust, Essex Cardiothorac Ctr, Basildon, Essex, England
[4] UCL, Inst Clin Trials & Methodol, London, England
[5] Anglia Ruskin Univ, Sch Med, Med Technol Res Ctr, Circulatory Hlth Res Grp, Chelmsford, England
[6] Nottingham Univ Hosp NHS Trust, Nottingham, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2024年 / 332卷 / 14期
关键词
CATHETER ABLATION; DENERVATION;
D O I
10.1001/jama.2024.17921
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance There are concerns that pulmonary vein isolation for atrial fibrillation may have a profound placebo effect, but no double-blind randomized clinical trials have been conducted. Objective To determine whether pulmonary vein isolation is more effective than a sham procedure for improving outcomes in atrial fibrillation. Design, Setting, and Participants Double-blind randomized clinical trial conducted at 2 tertiary centers in the UK between January 2020 and March 2024 among patients with symptomatic paroxysmal or persistent atrial fibrillation. Major exclusion criteria included long-standing persistent atrial fibrillation, prior left atrium ablation, other arrhythmias requiring ablative therapy, a left atrium of 5.5 cm or larger, and ejection fraction of less than 35%. Intervention Participants were randomly assigned to receive pulmonary vein isolation with cryoablation (n = 64) or a sham procedure with phrenic nerve pacing (n = 62). Main Outcomes and Measures The primary end point was atrial fibrillation burden at 6 months, excluding a 3-month blanking period. Secondary outcomes included quality-of-life measures, time to events, and safety. Atrial fibrillation burden was measured by an implantable loop recorder. Results A total of 126 participants were randomized (mean age, 66.8 years; 89 men [70.63%]; 20.63% with paroxysmal atrial fibrillation). The absolute mean atrial fibrillation burden change from baseline to 6 months was 60.31% in the ablation group and 35.0% in the sham group (geometric mean difference, 0.25; 95% CI, 0.15-0.42; P < .001). The estimated difference in the overall Atrial Fibrillation Effect on Quality of Life score at 6 months, favoring catheter ablation, was 18.39 points (95% CI, 11.48-25.30 points). The Short Form 36 general health score also improved substantially more with ablation, with an estimated difference of 9.27 points at 6 months (95% CI, 3.78-14.76 points). Conclusions and Relevance Pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation burden at 6 months, with substantial improvements in symptoms and quality of life, compared with a sham procedure.
引用
收藏
页码:1165 / 1173
页数:9
相关论文
共 21 条
  • [1] Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
    Al-Lamee, Rasha
    Thompson, David
    Dehbi, Hakim-Moulay
    Sen, Sayan
    Tang, Kare
    Davies, John
    Keeble, Thomas
    Mielewczik, Michael
    Kaprielian, Raffi
    Malik, Iqbal S.
    Nijjer, Sukhjinder S.
    Petraco, Ricardo
    Cook, Christopher
    Ahmad, Yousif
    Howard, James
    Baker, Christopher
    Sharp, Andrew
    Gerber, Robert
    Talwar, Suneel
    Assomull, Ravi
    Mayet, Jamil
    Wensel, Roland
    Collier, David
    Shun-Shin, Matthew
    Thom, Simon A.
    Davies, Justin E.
    Francis, Darrel P.
    [J]. LANCET, 2018, 391 (10115) : 31 - 40
  • [2] Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring A Randomized Clinical Trial
    Andrade, Jason G.
    Champagne, Jean
    Dubuc, Marc
    Deyell, Marc W.
    Verma, Atul
    Macle, Laurent
    Leong-Sit, Peter
    Novak, Paul
    Badra-Verdu, Mariano
    Sapp, John
    Mangat, Iqwal
    Khoo, Clarence
    Steinberg, Christian
    Bennett, Matthew T.
    Tang, Anthony S. L.
    Khairy, Paul
    Parkash, Ratika
    Guerra, Peter
    Dyrda, Katia
    Rivard, Lena
    Racine, Normand
    Sterns, Lawrence
    Leather, Rick
    Seifer, Colette
    Jolly, Umjeet
    Raymond, Jean-Marc
    Roux, Jean-Francois
    Nault, Isabelle
    Sarrazin, Jean-Francois
    Ramanathan, Krishnan
    Cheung, Christopher
    Fordyce, Christopher
    McKinney, Jimmy
    Luong, Christina
    Rizkallah, Jacques
    Angaran, Paul
    Ha, Andrew
    Glover, Benedict
    Skanes, Allan
    Gula, Lorne
    [J]. CIRCULATION, 2019, 140 (22) : 1779 - 1788
  • [3] Assessment of blinding in clinical trials
    Bang, HJ
    Ni, LY
    Davis, CE
    [J]. CONTROLLED CLINICAL TRIALS, 2004, 25 (02): : 143 - 156
  • [4] A Controlled Trial of Renal Denervation for Resistant Hypertension
    Bhatt, Deepak L.
    Kandzari, David E.
    O'Neill, William W.
    D'Agostino, Ralph
    Flack, John M.
    Katzen, Barry T.
    Leon, Martin B.
    Liu, Minglei
    Mauri, Laura
    Negoita, Manuela
    Cohen, Sidney A.
    Oparil, Suzanne
    Rocha-Singh, Krishna
    Townsend, Raymond R.
    Bakris, George L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15) : 1393 - 1401
  • [5] Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation The CAPTAF Randomized Clinical Trial
    Blomstrom-Lundqvist, Carina
    Gizurarson, Sigfus
    Schwieler, Jonas
    Jensen, Steen M.
    Bergfeldt, Lennart
    Kenneback, Goran
    Rubulis, Aigars
    Malmborg, Helena
    Raatikainen, Pekka
    Lonnerholm, Stefan
    Hoglund, Niklas
    Mortsell, David
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (11): : 1059 - 1068
  • [6] A randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (The SHAM-PVI study): Study design and rationale
    Dulai, Rajdip
    Furniss, Stephen S.
    Sulke, Neil
    Freemantle, Nick
    Lambiase, Pier D.
    Farwell, David
    Srinivasan, Neil T.
    Tan, Stuart
    Patel, Nikhil
    Graham, Adam
    Veasey, Rick A.
    [J]. CLINICAL CARDIOLOGY, 2023, 46 (08) : 973 - 980
  • [7] Hindricks G, 2021, EUR HEART J, V42, P546, DOI 10.1093/eurheartj/ehaa945
  • [8] Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
    Holmes, DaJuanicia N.
    Piccini, Jonathan P.
    Allen, Larry A.
    Fonarow, Gregg C.
    Gersh, Bernard J.
    Kowey, Peter R.
    O'Brien, Emily C.
    Reiffel, James A.
    Naccarelli, Gerald V.
    Ezekowitz, Michael D.
    Chan, Paul S.
    Singer, Daniel E.
    Spertus, John A.
    Peterson, Eric D.
    Thomas, Laine
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2019, 12 (05):
  • [9] Kirchhof P, 2016, EUROPACE, V18, DOI [10.1016/j.rec.2016.11.033, 10.1093/europace/euw295, 10.5603/KP.2016.0172]
  • [10] On Efficiency of Constrained Longitudinal Data Analysis Versus Longitudinal Analysis of Covariance
    Lu, Kaifeng
    [J]. BIOMETRICS, 2010, 66 (03) : 891 - 896